Neuroinflammation in the Central Nervous System: Exploring the Evolving Influence of Endocannabinoid System

Neuroinflammation is a complex biological process that typically originates as a protective response in the brain. This inflammatory process is triggered by the release of pro-inflammatory substances like cytokines, prostaglandins, and reactive oxygen and nitrogen species from stimulated endothelial and glial cells, including those with pro-inflammatory functions, in the outer regions. While neuronal inflammation is common in various central nervous system disorders, the specific inflammatory pathways linked with different immune-mediated cell types and the various factors influencing the blood-brain barrier significantly contribute to disease-specific characteristics. The endocannabinoid system consists of cannabinoid receptors, endogenous cannabinoids, and enzymes responsible for synthesizing and metabolizing endocannabinoids. The primary cannabinoid receptor is CB1, predominantly found in specific brain regions such as the brainstem, cerebellum, hippocampus, and cortex. The presence of CB2 receptors in certain brain components, like cultured cerebellar granular cells, Purkinje fibers, and microglia, as well as in the areas like the cerebral cortex, hippocampus, and cerebellum is also evidenced by immunoblotting assays, radioligand binding, and autoradiography studies. Both CB1 and CB2 cannabinoid receptors exhibit noteworthy physiological responses and possess diverse neuromodulatory capabilities. This review primarily aims to outline the distribution of CB1 and CB2 receptors across different brain regions and explore their potential roles in regulating neuroinflammatory processes.

[1]  Yogeeta O. Agrawal,et al.  Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer's Disease. , 2023, Current drug research reviews.

[2]  M. Tremblay,et al.  All roads lead to heterogeneity: The complex involvement of astrocytes and microglia in the pathogenesis of Alzheimer’s disease , 2022, Frontiers in Cellular Neuroscience.

[3]  M. Tremblay,et al.  Present and future of microglial pharmacology. , 2022, Trends in pharmacological sciences.

[4]  Q. Pittman,et al.  Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase , 2021, Neuropsychopharmacology.

[5]  Jie Wu,et al.  The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders , 2020, Acta Pharmacologica Sinica.

[6]  J. Tytgat,et al.  Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products , 2020, International journal of molecular sciences.

[7]  M. Tansey,et al.  Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease , 2020, Molecules.

[8]  R. Mechoulam Cannabinoids as Therapeutic Agents , 2019 .

[9]  Junxia Xie,et al.  Mechanisms of cannabinoid CB2 receptor-mediated reduction of dopamine neuronal excitability in mouse ventral tegmental area , 2019, EBioMedicine.

[10]  I. Ferrer,et al.  Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system , 2018, Biochemical pharmacology.

[11]  T. Uyama,et al.  Endocannabinoids and related N-acylethanolamines: biological activities and metabolism , 2018, Inflammation and Regeneration.

[12]  M. Heneka,et al.  Microglia: You'll Never Walk Alone! , 2018, Immunity.

[13]  B. Blomberg,et al.  Aging, Obesity, and Inflammatory Age-Related Diseases , 2017, Front. Immunol..

[14]  Jimok Kim,et al.  Distinct roles of neuronal and microglial CB2 cannabinoid receptors in the mouse hippocampus , 2017, Neuroscience.

[15]  Jeremy Hall,et al.  Modulating Neuroinflammation to Treat Neuropsychiatric Disorders , 2017, BioMed research international.

[16]  A. Vezzani,et al.  Inflammation and Epilepsy: Preclinical Findings and Potential Clinical Translation. , 2017, Current pharmaceutical design.

[17]  M. Hočevar,et al.  Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer's disease. , 2017, European journal of pharmacology.

[18]  B. Basavarajappa,et al.  Endocannabinoid system in neurodegenerative disorders , 2017, Journal of neurochemistry.

[19]  R. Thangavel,et al.  Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration , 2017, Front. Cell. Neurosci..

[20]  A. Lichtman,et al.  Endocannabinoids: A Promising Impact for Traumatic Brain Injury , 2017, Front. Pharmacol..

[21]  A. Romano,et al.  Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target , 2017, Front. Neurosci..

[22]  Jie Wu,et al.  Brain cannabinoid receptor 2: expression, function and modulation , 2017, Acta Pharmacologica Sinica.

[23]  P. Campolongo,et al.  Emotional arousal state influences the ability of amygdalar endocannabinoid signaling to modulate anxiety , 2016, Neuropharmacology.

[24]  K. Herrup,et al.  Family-wide Structural Characterization and Genomic Comparisons Decode the Diversity-oriented Biosynthesis of Thalassospiramides by Marine Proteobacteria* , 2016, The Journal of Biological Chemistry.

[25]  S. Skaper Mast Cell - Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications. , 2016, CNS & neurological disorders drug targets.

[26]  M. Schwartz,et al.  Neurological Disease as a Failure of Brain-Immune Crosstalk: The Multiple Faces of Neuroinflammation. , 2016, Trends in immunology.

[27]  J. Foss,et al.  Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a chronic post‐ischemic pain model of complex regional pain syndrome type I in rats , 2016, The European journal of neuroscience.

[28]  D. Marasco,et al.  Endocannabinoid System in Neurological Disorders. , 2016, Recent patents on CNS drug discovery.

[29]  A. Papanicolaou,et al.  Transcriptome Analysis of the Sydney Rock Oyster, Saccostrea glomerata: Insights into Molluscan Immunity , 2016, PloS one.

[30]  D. Schmitz,et al.  Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus , 2016, Neuron.

[31]  Sudhakar Selvaraj,et al.  Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness , 2016, Psychopharmacology.

[32]  T. Kielian Multifaceted roles of neuroinflammation: the need to consider both sides of the coin , 2016, Journal of neurochemistry.

[33]  J. Ting,et al.  The pathogenic role of the inflammasome in neurodegenerative diseases , 2016, Journal of neurochemistry.

[34]  H. Baik,et al.  CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease , 2016, Experimental & Molecular Medicine.

[35]  S. Skaper Commentary. Low-grade non-resolving neuroinflammation: age does matter. , 2015, CNS & neurological disorders drug targets.

[36]  R. Marotta,et al.  Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids. , 2015, Structure.

[37]  J. Manzanares,et al.  Role of cannabinoid CB2 receptor in the reinforcing actions of ethanol , 2015, Addiction biology.

[38]  Zheng-Xiong Xi,et al.  Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice , 2014, Proceedings of the National Academy of Sciences.

[39]  Shruti V. Kabadi,et al.  Repeated Mild Traumatic Brain Injury Causes Chronic Neuroinflammation, Changes in Hippocampal Synaptic Plasticity, and Associated Cognitive Deficits , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  G. Panagis,et al.  Regulation of brain reward by the endocannabinoid system: a critical review of behavioral studies in animals. , 2014, Current pharmaceutical design.

[41]  P. Diaz,et al.  Spinal gene expression profiling and pathways analysis of a CB2 agonist (MDA7)-targeted prevention of paclitaxel-induced neuropathy , 2014, Neuroscience.

[42]  B. Stevens,et al.  Phagocytic glial cells: sculpting synaptic circuits in the developing nervous system , 2013, Current Opinion in Neurobiology.

[43]  P. Goadsby,et al.  Endocannabinoids in the Brainstem Modulate Dural Trigeminovascular Nociceptive Traffic via CB1 and “Triptan” Receptors: Implications in Migraine , 2013, The Journal of Neuroscience.

[44]  J. Manzanares,et al.  Role of CB2 Cannabinoid Receptors in the Rewarding, Reinforcing, and Physical Effects of Nicotine , 2013, Neuropsychopharmacology.

[45]  A. Vezzani Fetal brain inflammation may prime hyperexcitability and behavioral dysfunction later in life , 2013, Annals of neurology.

[46]  V. Brázda,et al.  Bilateral Changes of Cannabinoid Receptor Type 2 Protein and mRNA in the Dorsal Root Ganglia of a Rat Neuropathic Pain Model , 2013, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[47]  D. Selley,et al.  Brain regional differences in CB1 receptor adaptation and regulation of transcription. , 2013, Life sciences.

[48]  R. Franco,et al.  CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients , 2013, Neurobiology of Aging.

[49]  Jijun Xu,et al.  Activation of the CB2 receptor system reverses amyloid-induced memory deficiency , 2013, Neurobiology of Aging.

[50]  R. Erzurumlu,et al.  Development of the principal nucleus trigeminal lemniscal projections in the mouse , 2013, The Journal of comparative neurology.

[51]  L. Petrocellis,et al.  Why do cannabinoid receptors have more than one endogenous ligand? , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[52]  C. Greyson,et al.  PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty , 2012, Journal of Lipid Research.

[53]  K. Varani,et al.  Cannabinoid CB2 receptor attenuates morphine‐induced inflammatory responses in activated microglial cells , 2012, British journal of pharmacology.

[54]  Garth E. Terry,et al.  Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers , 2012, Molecular Psychiatry.

[55]  Ben A. Barres,et al.  Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner , 2012, Neuron.

[56]  D. Cogdell,et al.  Prevention of Paclitaxel-Induced Neuropathy Through Activation of the Central Cannabinoid Type 2 Receptor System , 2012, Anesthesia and analgesia.

[57]  P. Chameau,et al.  Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors , 2012, Proceedings of the National Academy of Sciences.

[58]  Qing-Rong Liu,et al.  CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity , 2012, Journal of psychopharmacology.

[59]  I. Lizasoain,et al.  Cannabinoid Type 2 Receptor Activation Downregulates Stroke-Induced Classic and Alternative Brain Macrophage/Microglial Activation Concomitant to Neuroprotection , 2012, Stroke.

[60]  I. Galve-Roperh,et al.  CB2 Cannabinoid Receptors Promote Neural Progenitor Cell Proliferation via mTORC1 Signaling* , 2011, The Journal of Biological Chemistry.

[61]  L. Emadi,et al.  The role of central CB2 cannabinoid receptors on food intake in neonatal chicks , 2011, Journal of Comparative Physiology A.

[62]  L. Devi,et al.  The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications , 2011, Pharmacological Reviews.

[63]  Takeya Kasukawa,et al.  Quantitative Expression Profile of Distinct Functional Regions in the Adult Mouse Brain , 2011, PloS one.

[64]  Z. Xi,et al.  Brain Cannabinoid CB2 Receptors Modulate Cocaine’s Actions in Mice , 2011, Nature Neuroscience.

[65]  B. Dittel,et al.  Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease , 2011, Immunologic research.

[66]  J. Manzanares,et al.  Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice , 2011, Neuropsychopharmacology.

[67]  A. Majewska,et al.  A role for microglia in synaptic plasticity? , 2011, Communicative & integrative biology.

[68]  A. Świergiel,et al.  Cannabidiol decreases body weight gain in rats: Involvement of CB2 receptors , 2011, Neuroscience Letters.

[69]  J. Manzanares,et al.  Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice , 2011, Journal of psychopharmacology.

[70]  Ania K. Majewska,et al.  Microglial Interactions with Synapses Are Modulated by Visual Experience , 2010, PLoS biology.

[71]  Miguel Martín,et al.  Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age , 2010, Diabetologia.

[72]  J. Manzanares,et al.  Depression‐resistant endophenotype in mice overexpressing cannabinoid CB2 receptors , 2010, British journal of pharmacology.

[73]  N. Stella Cannabinoid and cannabinoid‐like receptors in microglia, astrocytes, and astrocytomas , 2010, Glia.

[74]  K. Mackie,et al.  CB2: a cannabinoid receptor with an identity crisis , 2010, British journal of pharmacology.

[75]  J. Hallak,et al.  [Therapeutical use of the cannabinoids in psychiatry]. , 2010, Revista brasileira de psiquiatria.

[76]  V. D. M. A. L. D. Petrocellis Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. , 2010 .

[77]  P. Reggio Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. , 2010, Current medicinal chemistry.

[78]  B. Vergès,et al.  CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice , 2010, Diabetes.

[79]  Rodney W. Johnson,et al.  Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. , 2009, Rejuvenation research.

[80]  Claudio N. Cavasotto,et al.  2,3‐Dihydro‐1‐Benzofuran Derivatives as a Series of Potent Selective Cannabinoid Receptor 2 Agonists: Design, Synthesis, and Binding Mode Prediction through Ligand‐Steered Modeling , 2009, ChemMedChem.

[81]  K. Psarra,et al.  Anandamide Increases the Differentiation of Rat Adipocytes and Causes PPARγ and CB1 Receptor Upregulation , 2009, Obesity.

[82]  G. Uhl,et al.  CNS Effects of CB2 Cannabinoid Receptors , 2009 .

[83]  J. Martínez-Orgado,et al.  The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages , 2009, Brain Research.

[84]  G. Uhl,et al.  Functional Expression of Brain Neuronal CB2 Cannabinoid Receptors Are Involved in the Effects of Drugs of Abuse and in Depression , 2008, Annals of the New York Academy of Sciences.

[85]  E. Romero-Sandoval,et al.  Neuroimmune interactions and pain: focus on glial-modulating targets. , 2008, Current opinion in investigational drugs.

[86]  Xiaolu Yang,et al.  TIPE2, a Negative Regulator of Innate and Adaptive Immunity that Maintains Immune Homeostasis , 2008, Cell.

[87]  K. Mackie,et al.  Cannabinoid Receptors: Where They are and What They do , 2008, Journal of neuroendocrinology.

[88]  J. Deleo,et al.  Spinal Microglial and Perivascular Cell Cannabinoid Receptor Type 2 Activation Reduces Behavioral Hypersensitivity without Tolerance after Peripheral Nerve Injury , 2008, Anesthesiology.

[89]  A. Mallat,et al.  CB2 receptors as new therapeutic targets for liver diseases , 2008, British journal of pharmacology.

[90]  K. Wright,et al.  Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation , 2008, British journal of pharmacology.

[91]  N. E. Buckley The peripheral cannabinoid receptor knockout mice: an update , 2008, British journal of pharmacology.

[92]  A. Hohmann,et al.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain , 2008, British journal of pharmacology.

[93]  C. Guaza,et al.  CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies , 2008, British journal of pharmacology.

[94]  N. Stella,et al.  CB2 receptor‐mediated migration of immune cells: it can go either way , 2008, British journal of pharmacology.

[95]  J. Eisenach,et al.  Spinal Cannabinoid Receptor Type 2 Activation Reduces Hypersensitivity and Spinal Cord Glial Activation after Paw Incision , 2007, Anesthesiology.

[96]  J. Villares Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain , 2007, Neuroscience.

[97]  V. Marzo,et al.  Endocannabinoids and the control of energy balance , 2007, Trends in Endocrinology & Metabolism.

[98]  M. Glass,et al.  Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain , 2007, Neuroscience Letters.

[99]  L. Petrocellis,et al.  Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain , 2006, Neuroscience.

[100]  R. Prediger,et al.  The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats , 2006, Psychopharmacology.

[101]  A. Zuardi History of cannabis as a medicine: a review. , 2006, Revista brasileira de psiquiatria.

[102]  Paul F. Smith,et al.  Expression of the cannabinoid CB2 receptor in the rat cerebellum: An immunohistochemical study , 2006, Neuroscience Letters.

[103]  R. Bertorelli,et al.  CB2 receptor‐mediated antihyperalgesia: possible direct involvement of neural mechanisms , 2006, The European journal of neuroscience.

[104]  G. Uhl,et al.  Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain , 2006, Brain Research.

[105]  B. Frenkel,et al.  Peripheral cannabinoid receptor, CB2, regulates bone mass. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[106]  R. Nitsch,et al.  The Endocannabinoid Anandamide Protects Neurons during CNS Inflammation by Induction of MKP-1 in Microglial Cells , 2006, Neuron.

[107]  P. McIntyre,et al.  Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons , 2005, Neuroscience.

[108]  E. Ponomarev,et al.  Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli , 2005, Journal of neurochemistry.

[109]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[110]  K. Mackie,et al.  A Glial Endogenous Cannabinoid System Is Upregulated in the Brains of Macaques with Simian Immunodeficiency Virus-Induced Encephalitis , 2005, The Journal of Neuroscience.

[111]  M. L. de Ceballos,et al.  Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation , 2005, The Journal of Neuroscience.

[112]  B. P. Kota,et al.  An overview on biological mechanisms of PPARs. , 2005, Pharmacological research.

[113]  A. Derbenev,et al.  Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve , 2004, The Journal of physiology.

[114]  D. Thompson,et al.  Expression of Cannabinoid CB1 Receptors by Vagal Afferent Neurons Is Inhibited by Cholecystokinin , 2004, The Journal of Neuroscience.

[115]  S. Ikeda,et al.  Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. , 2004, Molecular pharmacology.

[116]  Alberto Rábano,et al.  Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains , 2003, The Journal of Neuroscience.

[117]  T. Groblewski,et al.  Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models , 2003, The European journal of neuroscience.

[118]  S. Michalek,et al.  Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A , 2003, Infection and Immunity.

[119]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[120]  K. Waku,et al.  Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[121]  L. Acsády,et al.  Distribution of CB1 Cannabinoid Receptors in the Amygdala and their Role in the Control of GABAergic Transmission , 2001, The Journal of Neuroscience.

[122]  Anatol C. Kreitzer,et al.  Cerebellar Depolarization-Induced Suppression of Inhibition Is Mediated by Endogenous Cannabinoids , 2001, The Journal of Neuroscience.

[123]  George Kunos,et al.  Presynaptic Specificity of Endocannabinoid Signaling in the Hippocampus , 2001, Neuron.

[124]  M. Kano,et al.  Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals , 2001, Neuroscience Research.

[125]  B. Roques,et al.  Δ9‐tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect , 2001, The European journal of neuroscience.

[126]  K. Hsu,et al.  Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons , 2001, The Journal of physiology.

[127]  Sharon Anavi-Goffer,et al.  Agonist-Induced Internalization and Trafficking of Cannabinoid CB1 Receptors in Hippocampal Neurons , 2001, The Journal of Neuroscience.

[128]  R. Pertwee Cannabinoid receptors and pain , 2001, Progress in Neurobiology.

[129]  K. Connolly,et al.  Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids , 2001, Neuroscience Letters.

[130]  Anatol C. Kreitzer,et al.  Retrograde Inhibition of Presynaptic Calcium Influx by Endogenous Cannabinoids at Excitatory Synapses onto Purkinje Cells , 2001, Neuron.

[131]  O. Manzoni,et al.  Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens. , 2001, European journal of pharmacology.

[132]  David Robbe,et al.  Localization and Mechanisms of Action of Cannabinoid Receptors at the Glutamatergic Synapses of the Mouse Nucleus Accumbens , 2001, The Journal of Neuroscience.

[133]  T. Wenger,et al.  Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study☆ , 2000, Peptides.

[134]  T. Freund,et al.  GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus , 2000, Neuroscience.

[135]  I. Galve-Roperh,et al.  The CB1 Cannabinoid Receptor Is Coupled to the Activation of c-Jun N-Terminal Kinase , 2000 .

[136]  I. Módy,et al.  Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations , 2000, The European journal of neuroscience.

[137]  M. Elphick,et al.  Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C‐terminal tail of CB1 , 2000, The Journal of comparative neurology.

[138]  P. Soubrié,et al.  Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. , 2000, Journal of neurophysiology.

[139]  K. Mackie,et al.  Functional expression of cell surface cannabinoid CB1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons , 2000, Neuroscience.

[140]  T. Bonner,et al.  Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. , 2000, European journal of pharmacology.

[141]  A. Hoffman,et al.  Mechanisms of Cannabinoid Inhibition of GABAASynaptic Transmission in the Hippocampus , 2000, The Journal of Neuroscience.

[142]  D. Linden,et al.  Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. , 2000, Journal of neurophysiology.

[143]  E. E. Bagley,et al.  Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. , 2000, Molecular pharmacology.

[144]  Michael L. Eads,et al.  Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Δ9-THC and anandamide 1 Published on the World Wide Web on 18 January 2000. 1 , 2000, Brain Research.

[145]  P. Schweitzer Cannabinoids Decrease the K+ M-Current in Hippocampal CA1 Neurons , 2000, The Journal of Neuroscience.

[146]  G. Marsicano,et al.  Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain , 1999, The European journal of neuroscience.

[147]  R. Hampson,et al.  Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. , 1999, The Journal of pharmacology and experimental therapeutics.

[148]  J. G. Netzeband,et al.  Cannabinoids Enhance NMDA-Elicited Ca2+ Signals in Cerebellar Granule Neurons in Culture , 1999, The Journal of Neuroscience.

[149]  R. Mechoulam Recent Advantages in Cannabinoid Research , 1999, Complementary Medicine Research.

[150]  J. Sullivan,et al.  Mechanism of Cannabinoid Effects on Long-Term Potentiation and Depression in Hippocampal CA1 Neurons , 1999, The Journal of Neuroscience.

[151]  K. Mackie,et al.  Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation , 1999, Neuroscience.

[152]  K. Mackie,et al.  Internalization and Recycling of the CB1 Cannabinoid Receptor , 1999, Journal of neurochemistry.

[153]  S. McAllister,et al.  Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. , 1999, European journal of pharmacology.

[154]  A. Ameri The effects of cannabinoids on the brain , 1999, Progress in Neurobiology.

[155]  G. Cabral,et al.  Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. , 1999, The Journal of pharmacology and experimental therapeutics.

[156]  I. McGregor,et al.  Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro , 1999, British journal of pharmacology.

[157]  M. Herkenham,et al.  Cannabinoid receptors undergo axonal flow in sensory nerves , 1999, Neuroscience.

[158]  K. Mackie,et al.  Distinct Domains of the CB1 Cannabinoid Receptor Mediate Desensitization and Internalization , 1999, The Journal of Neuroscience.

[159]  K. Mackie,et al.  Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system , 1998, Neuroscience.

[160]  P. Casellas,et al.  Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. , 1998, The Journal of pharmacology and experimental therapeutics.

[161]  T. Herdegen,et al.  Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins , 1998, Brain Research Reviews.

[162]  R. Pertwee,et al.  Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice , 1998, Neuropharmacology.

[163]  P. Soubrié,et al.  Cannabinoids decrease excitatory synaptic transmission and impair long‐term depression in rat cerebellar Purkinje cells , 1998, The Journal of physiology.

[164]  K. Starke,et al.  Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum , 1998, Neuroscience.

[165]  W. Yung,et al.  Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist , 1998, Neuroreport.

[166]  R. Spencer,et al.  Immunohistochemical localization of the neural cannabinoid receptor in rat brain , 1998, Journal of neuroscience research.

[167]  J. Zentner,et al.  Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[168]  R. Pertwee,et al.  Action of δ-9-tetrahydrocannabinol on gabaa receptor-mediated responses in a grease-gap recording preparation of the rat hippocampal slice , 1997, Neuropharmacology.

[169]  Stephen P. H. Alexander,et al.  Influence of Cannabinoids on Electrically Evoked Dopamine Release and Cyclic AMP Generation in the Rat Striatum , 1997, Journal of neurochemistry.

[170]  M. Glass,et al.  Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Augments cAMP Accumulation in Striatal Neurons: Evidence for a Gs Linkage to the CB1 Receptor , 1997, The Journal of Neuroscience.

[171]  Sean P. Brown,et al.  Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. , 1997, Journal of neurophysiology.

[172]  N. Kaminski,et al.  Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. , 1997, Toxicology and applied pharmacology.

[173]  S. Deadwyler,et al.  Role of cyclic AMP in the actions of cannabinoid receptors. , 1996, Biochemical pharmacology.

[174]  P. Casellas,et al.  Characterization of two cloned human CB1 cannabinoid receptor isoforms. , 1996, The Journal of pharmacology and experimental therapeutics.

[175]  J. Brotchie,et al.  Activation of the cannabinoid receptor by Δ9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus , 1996 .

[176]  M. Shen,et al.  Cannabinoid Receptor Agonists Inhibit Glutamatergic Synaptic Transmission in Rat Hippocampal Cultures , 1996, The Journal of Neuroscience.

[177]  C. Ashby,et al.  Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. , 1996, The Journal of pharmacology and experimental therapeutics.

[178]  A. Buriani,et al.  The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[179]  P. Casellas,et al.  Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. , 1995, The Biochemical journal.

[180]  P. Soubrié,et al.  Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[181]  S. Galiègue,et al.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.

[182]  J. Walker,et al.  Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. , 1995, European journal of pharmacology.

[183]  M. Kaghad,et al.  An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing (*) , 1995, The Journal of Biological Chemistry.

[184]  R. Pertwee,et al.  The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. , 1994, European journal of pharmacology.

[185]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[186]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[187]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[188]  N. Bowery,et al.  GABAA and GABAB receptor site distribution in the rat central nervous system , 1987, Neuroscience.

[189]  R. Razdan,et al.  Structure-activity relationships of the cannabinoids. , 1986, NIDA research monograph.

[190]  L E Hollister,et al.  Health aspects of cannabis. , 1986, Pharmacological reviews.

[191]  J. Penney,et al.  Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[192]  W. Dewey,et al.  Some 9-hydroxycannabinoid-like compounds. Synthesis and evaluation of analgesic and behavioral properties. , 1979, Journal of medicinal chemistry.

[193]  B. Martin,et al.  9-Nor-9-hydroxyhexahydrocannabinols. Synthesis, Some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols. , 1976, Journal of medicinal chemistry.

[194]  E. May,et al.  Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. , 1975, Journal of medicinal chemistry.

[195]  R. Mechoulam,et al.  Chemical Basis of Hashish Activity , 1970, Science.

[196]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .

[197]  On the Preparations of the Indian Hemp, or Gunjah (Cannabis Indica), Their Effects on the Animal System in Health, and Their Utility in the Treatment of Tetanus and Other Convulsive Diseases , 1840, The British and foreign medical review.

[198]  Salvatore Chirumbolo,et al.  Immune dysfunction and neuroinflammation in autism spectrum disorder. , 2016, Acta neurobiologiae experimentalis.

[199]  L. Zweifel,et al.  Behavioral effects of pulp exposure in mice lacking cannabinoid receptor 2. , 2012, Journal of endodontics.

[200]  V. Di Marzo,et al.  Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. , 2010, Current medicinal chemistry.

[201]  V. Di Marzo,et al.  Role of endocannabinoids and endovanilloids in Ca2+ signalling. , 2009, Cell calcium.

[202]  Robert A. Smith,et al.  Permissive and repulsive cues and signalling pathways of axonal outgrowth and regeneration. , 2008, International review of cell and molecular biology.

[203]  G. Velasco,et al.  Cannabinoid CB2 receptor: a new target for controlling neural cell survival? , 2007, Trends in pharmacological sciences.

[204]  G. Guy,et al.  A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. , 2006, Medical hypotheses.

[205]  L. Sim-Selley,et al.  Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. , 2003, Critical reviews in neurobiology.

[206]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[207]  A. Hoffman,et al.  Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids. , 2001, Journal of neurophysiology.

[208]  D. Lovinger,et al.  CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. , 2001, Journal of neurophysiology.

[209]  M. Thiébot,et al.  Behavioral Effects of Cannabinoid Agents in Animals. , 1999, Critical reviews in neurobiology.

[210]  R. Pertwee Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[211]  A. Howlett,et al.  Pharmacology of cannabinoid receptors. , 1995, Annual review of pharmacology and toxicology.

[212]  W. Dewey Cannabinoid pharmacology. , 1986, Pharmacological reviews.

[213]  K. Mackie,et al.  Identification functional characterization of brainstem cannabinoid CB2 receptors. , 2022 .